重度の心不全において,イノトロピーおよび血管拡張薬の血液動力学的効果を比較する
Circulation
|October 1, 1977
まとめ
重度の閉塞性心不全 (CHF) の患者は,ドブタミンとナトリウムニトロプルシドで同様の心臓出力増加を示しました. これらの薬剤を併用すると,心臓の機能がさらに改善され,血管抵抗性が低下しました.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- クリティカルケア・メディシン
背景:
- 重度の閉塞性心不全 (CHF) の管理には,心臓の出力を最適化し,血管抵抗を減らす必要があります.
- 静脈内でのイノトロピー剤と血管拡張剤は,CHFの重要な治療法である.
- ドブタミンとナトリウムニトロプロシドの比較および併合の血液動力学的効果を理解することは,治療戦略にとって極めて重要です.
研究 の 目的:
- 重度のCHF患者の静脈内ナトリウムニトロプルシドとドブタミンの血動力学的反応を比較する.
- ニトロプロシドナトリウムとドブタミンの心臓機能と血管抵抗に対する併用効果を評価する.
- CHFにおけるドブタミンとナトリウムニトロプロシドの血管拡張性特性を調査する.
主な方法:
- ヘモダイナミックパラメータは,静脈注射ナトリウムニトロプロシドまたはドブタミンを受けた12人の重度のCHF患者で測定されました.
- さらに5人の患者を対象に,両薬の分離注入および併用注入を行った.
- 投与量依存の血管拡張は,腕動脈注入によって評価されました.
主要な成果:
- ドブタミンとナトリウムニトロプロシドの両方,心臓の出力 (CO) を有意に増加させた.
- ドブタミンは,高血圧と高心率をもたらし,ナトリウムニトロプロシドと比較して,肺圧 (PWP) の低下が少ない.
- 併用輸液は,いずれかの薬剤単独よりも優れたCO,低いPWP,および全身および肺血管抵抗のより大きな減少をもたらしました.
結論:
- ドブタミンやナトリウムニトロプロシドのような強力なイノトロピーおよび血管拡張薬は,心不全における左心室の機能に追加的な利点を提供します.
- ドブタミンの血管拡張は,潜在的に反射媒介され,そのポジティブなイノトロプ効果と心臓の出力増加に大きく貢献します.
- ドブタミンとナトリウムニトロプロシドの併用療法は,重度の心不全の血液動力学を管理するための強力な戦略です.
関連する概念動画
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:26Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...